Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 12/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | CD69 | Q07108 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077746 | 0.88 | SELE (0.50) | SELEMAPK1ALDH1A1THRB | |
| SCHEMBL13077385 | 0.87 | SELE (0.49) | SELELGALS3 | |
| SCHEMBL13077057 | 0.78 | SELE (0.57) | SELELGALS3LGALS4 | |
| SCHEMBL19479229 | 0.78 | SELE (0.44) | SELEMAPK1ALDH1A1THRB | |
| SCHEMBL19479292 | 0.78 | SELE (0.52) | SELEMAPK1ALDH1A1THRB | |
| SCHEMBL17881699 | 0.77 | SELE (0.45) | SELEMAPK1ALDH1A1THRB | |
| SCHEMBL16659817 | 0.76 | SELE (0.74) | SELEMAPK1 | |
| SCHEMBL18653472 | 0.76 | SELE (0.64) | SELEMAPK1 | |
| SCHEMBL22798303 | 0.76 | SELE (0.64) | SELEMAPK1 | |
| SCHEMBL21206347 | 0.75 | SELE (0.69) | SELEMAPK1ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279965-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279965-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | CXCL12, CXCR4, SELE | SELE 3/4885MAPK1 2516/4885ALDH1A1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.